Código QR

Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis

There is no uniform regimen for refractory Langerhans cell histiocytosis (LCH). We retrospectively described patients with refractory multisystem and risk organ involvement LCH treated with the low-dose (Ara-c, 100 mg/m2/d × 5day; 2-CDA, 5 mg/m2/d × 5day) chemotherapy (LDC) and the intermediate-dose...

Descrición completa

Gardado en:
Principais autores: Wenqian Wang, Jian Ge, Honghao Ma, Hongyun Lian, Lei Cui, Yunze Zhao, Zhigang Li, Tianyou Wang, Rui Zhang
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2023-09-01
Series:Heliyon
Assuntos:
Langerhans cell histiocytosis
Refractory
Risk organ
Cytarabine
Cladribine
Acceso en liña:http://www.sciencedirect.com/science/article/pii/S240584402306485X
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares